Diagnostic and therapeutic approach of systemic amyloidosis

Netherlands Journal of Medicine

Volumn 62, Issue 4, 2004, Pages 121-128

  Hazenberg, B P C ^a   van Gameren, I I ^a   Bijzet, J ^a   Jager, P L ^a   van Rijswijk, M H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 PROPANEDISULFONIC ACID; 4' IODOESORUBICIN; ADALIMUMAB; AMITRIPTYLINE; AMYLOID A PROTEIN; AMYLOID P COMPONENT; AMYLOID PRECURSOR PROTEIN; AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; CHLORAMBUCIL; CISAPRIDE; COLCHICINE; CONGO RED; CYCLOPHOSPHAMIDE; DIGOXIN; DIMETHYL SULFOXIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ETANERCEPT; FLUDROCORTISONE; GLYCOSAMINOGLYCAN; IMMUNOGLOBULIN LIGHT CHAIN; INFLIXIMAB; MELPHALAN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREALBUMIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SODIUM 1,3 PROPANE DISULFONATE; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGING; AMYLOIDOSIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BETA SHEET; BINDING AFFINITY; CARDIOTOXICITY; CHRONIC INFLAMMATION; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG CHOICE; DRUG MECHANISM; DRUG PROTEIN BINDING; FOLLOW UP; GENE MUTATION; HEART FAILURE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSCINTIGRAPHY; NEUROPATHIC PAIN; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN DEGRADATION; REVIEW; SYMPTOMATOLOGY; TORSADE DES POINTES;

AMYLOID; AMYLOIDOSIS; HUMANS; PROGNOSIS;

EID: 4143063623     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337:898-909.
2. Westermark P, Benson MD, Buxbaum JN, et al. Amyloid fibril protein nomenclature - 2002. Amyloid J Protein Folding Disord 2002;9:197-200.
3. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-96.
4. Kay J. β2-microglobulin amyloidosis. Amyloid Int J Exp Clin Invest 1997;4:187-211.
5. Kamphuis AGA, Geerlings W, Hazenberg BPC, Thijn CJP. Annual evaluation of hip joints and hands for radiographic signs of Aβ2M-amyloidosis in long-term hemodialysis patients. Skeletal Radiol 1994;23:421-7.
6. Breedveld FC, Markusse HM, MacFarlane JD. Subcutaneous fat biopsy in the diagnosis of amyloidosis secondary to chronic arthritis. Clin Exp Rheumatol 1989;7:407-10.
7. Klemi PJ, Sorsa S, Happonen RP. Fine-needle aspiration biopsy from subcutaneous fat. An easy way to diagnose secondary amyloidosis. Scand J Rheumatol 1987;16:429-31.
8. Kyle RA, Gertz MA. Primary systemic amyloidosis: Clinical and laboratory features in 474 Cases. Semin Hematol 1995;32:45-59.
9. Janssen S, Rijswijk MH van, Meijer S, Ruinen L, Hem GK van der. Systemic amyloidosis: a clinical survey of 144 cases. Neth J Med 1986;29:376-85.
10. Röcken C, Sletten K. Amyloid in surgical pathology. Virchows Arch 2003;443:3-16:
11. Hazenberg BPC, Grond J, Top D van de, Bijzet J, Limburg PC, Rijswijk MH van. Detection of amyloid AA in rectal biopsies with a new monoclonal anti-human SAA antibody (Reu.86.2). Kidney Int 1991;40:976-7.
12. Hazenberg BPC, Limburg PC, Bijzet J, Rijswijk MH van. A quantitative method for detecting deposits of amyloid A protein in aspirated fat tissue of patients with arthritis. Ann Rheum Dis 1999;58:96-102.
13. Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002;346:1786-91.
14. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346:564-9.
15. Lachmann HJ, Gallimore R, Gillmore J, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003;122:78-84.
16. Reyners AKL, Hazenberg BPC, Haagsma EB, Tio RA, Reitsma WD, Smit AJ. The assessment of autonomic function in patients with systemic amyloidosis: methodological considerations. Amyloid Int J Exp Clin Invest 1998;5:193-9.
17. Reyners AKL, Hazenberg BPC, Reitsma WD, Smit AJ. Heart rate variability as a predictor of mortality in patients with AA and AL amyloidosis. Eur Heart J 2002;23:157-61.
18. Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 1231-labeled serum amyloid P component. N Engl J Med 1990;323:508-13
19. Jager PL, Hazenberg BPC, Franssen EJF, Limburg PC, Rijswijk MH van, Piers DA. Kinetic studies with Iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value. J Nucl Med 1998;39:699-706.
20. Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001;358:24-9.
21. Rijswijk MH van. Amyloidosis. Groningen: University of Groningen, 1981.
22. Dode C, Hazenberg BPC, Pecheux C, et al. Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. Nephrol Dial Transplant 2002;17:1212-7.
23. Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003;348:2583-4.
24. Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 1986;314:1001-5.
25. Rijswijk MH van, Ruinen L, Donker AJ, de Blecourt JJ, Mandema E. Dimethylsulfoxide in the treatment of AA amyloidosis. Ann N Y Acad Sci 1983;41167-83.
26. Iwakiri R, Sakemi T, Fujimoto K. Dimethylsulfoxide for renal dysfunction caused by systemic amyloidosis complicating Crohn's disease. Gastroenterology 1999;117:1031-2.
27. Comenzo RL, Vosburgh E, Falk RH, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (Amyloid light-chain) amyloidosis: Survival and responses in 25 patients. Blood 1998;91:3662-70.
28. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85-93.
29. Ericzon B-G, Larsson M, Herlenius G, Wilczek HE, on behalf of reporting members of the FAPWTR. Report from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR) and the Domino Liver Transplant Registry (DLTR). Amyloid J Protein Folding Disord 2003;10(suppl 1):67-76.
30. Gameren II van, Hazenberg BPC, Jager PL, Smit JW, Vellenga E. AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation. Amyloid J Protein Folding Disord 2002;9:165-74.
31. Hawkins PN, Richardson S, MacSweeney JE, et al. Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for turnover and regression. QJM 1993;86:365-74.
32. Inoue S, Hultin PG, Szarek WA, Kisilevsky R. Effect of poly(vinylsulfonate) on murine AA amyloid: a high-resolution ultrastructural study. Lab Invest 1996;74:1081-90.
33. Gertz MA, Lacy MQ, Dispenzieri A, et al. A multicenter phase II trial of 4′-iodo-deoxydoxorubicin (IDOX) in primary amyloidosis (AL). Amyloid J Protein Folding Disord 2002;9:24-30.
34. Pepys MB, Herbert J, Hutchingson WL, et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002;417:254-9.
35. Hammarstrom P, Wiseman RL, Powers ET, Kelly JW. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 2003;299:713-7.
36. Hrncic R, Wall J, Wolfenbarger DA, et al. Anti body-mediated resolution of light chain-associated amyloid deposits. Am J Pathol 2000;157:1239-46.